Clinical trial NCT00136942: A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Official title: A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hyperlipidemia
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-08-29
Enrollment: 370
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.


Eligibility criteria: Inclusion Criteria:

* Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
* LDL-C \< 6.0 mmol/l
* Triglyceride level \< 5.0 mmol/l.

Exclusion Criteria:

* Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Primary outcomes:
measure: The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Secondary outcomes:
measure: The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Other outcomes:
Locations:
city: Langenthal
country: Switzerland
facility: Pfizer Investigational Site
state: BE
city: Thun
country: Switzerland
facility: Pfizer Investigational Site
state: BE
city: Binningen
country: Switzerland
facility: Pfizer Investigational Site
state: BL
city: Liestal
country: Switzerland
facility: Pfizer Investigational Site
state: BL
city: Basel
country: Switzerland
facility: Pfizer Investigational Site
state: BS
city: Duedingen
country: Switzerland
facility: Pfizer Investigational Site
state: FR
city: Geneve
country: Switzerland
facility: Pfizer Investigational Site
state: GE
city: Onex
country: Switzerland
facility: Pfizer Investigational Site
state: GE
city: Pfaeffikon
country: Switzerland
facility: Pfizer Investigational Site
state: SZ
city: Siebnen
country: Switzerland
facility: Pfizer Investigational Site
state: SZ
city: Lugano
country: Switzerland
facility: Pfizer Investigational Site
state: TI
city: Malvaglia
country: Switzerland
facility: Pfizer Investigational Site
state: TI
city: Melide
country: Switzerland
facility: Pfizer Investigational Site
state: TI
city: Vezia
country: Switzerland
facility: Pfizer Investigational Site
state: TI
city: Ecublens
country: Switzerland
facility: Pfizer Investigational Site
state: VD
city: Lausanne
country: Switzerland
facility: Pfizer Investigational Site
state: VD
city: Prilly
country: Switzerland
facility: Pfizer Investigational Site
state: VD
city: Unteraegeri
country: Switzerland
facility: Pfizer Investigational Site
state: ZG
city: Zug
country: Switzerland
facility: Pfizer Investigational Site
state: ZG
city: Zuerich
country: Switzerland
facility: Pfizer Investigational Site
state: ZH
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: